Search research articles
Contact Us
Filters
Showing results (171-180 of 302) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2007
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
Bruno P Coudert, Remy Largillier, Laurent Arnould, et al.
Scientific Reports
|
November 12, 2021
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
Loïg Vaugier, Loïc Ah-Thiane, Maud Aumont, et al.
Cancers
|
November 26, 2022
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)
Valérie Seegers, Guillaume Rousseau, Ke Zhou, et al.
Clinical Medicine Insights. Oncology
|
April 25, 2022
COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)
Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, et al.
Breast Cancer Research : BCR
|
November 3, 2011
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, et al.
Oncotarget
|
April 30, 2016
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
Anthony Kong, Daniel Rea, Samreen Ahmed, et al.
Cancer Research
|
August 19, 2016
Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations
Yu Fu, Cécile Jovelet, Thomas Filleron, et al.
ESMO Open
|
July 16, 2020
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Mark Rosenthal, Paul M Clement, Mario Campone, et al.
Molecular & Cellular Proteomics : MCP
|
October 12, 2011
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker
Damien Besson, Aude-Hélène Pavageau, Isabelle Valo, et al.
Page
of 31
Search research articles
Search
Showing results (171-180 of 302) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2007
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
Bruno P Coudert, Remy Largillier, Laurent Arnould, et al.
Scientific Reports
|
November 12, 2021
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
Loïg Vaugier, Loïc Ah-Thiane, Maud Aumont, et al.
Cancers
|
November 26, 2022
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)
Valérie Seegers, Guillaume Rousseau, Ke Zhou, et al.
Clinical Medicine Insights. Oncology
|
April 25, 2022
COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)
Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, et al.
Breast Cancer Research : BCR
|
November 3, 2011
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, et al.
Oncotarget
|
April 30, 2016
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
Anthony Kong, Daniel Rea, Samreen Ahmed, et al.
Cancer Research
|
August 19, 2016
Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations
Yu Fu, Cécile Jovelet, Thomas Filleron, et al.
ESMO Open
|
July 16, 2020
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Mark Rosenthal, Paul M Clement, Mario Campone, et al.
Molecular & Cellular Proteomics : MCP
|
October 12, 2011
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker
Damien Besson, Aude-Hélène Pavageau, Isabelle Valo, et al.
Page
of 31